Latest Ionis News & Updates

See the latest news and media coverage for Ionis. We track all announcements, press releases, and industry mentions in real time, all in one place.

Ionis

RNA- and DNA-targeted medicines developer

ionis.com

Headquarters: Carlsbad, United States
Founded year: 1989
Company type: Public company
Number of employees: 500–1,600
Industry: Pharmaceuticals

Last updated Today

Latest news about Ionis

In short: Ionis Pharmaceuticals secured FDA approval for Tryngolza while advancing several late-stage therapies for rare and cardiovascular diseases.

Company announcements

July 29 Ionis

Ionis reports second quarter 2026 financial results

Revenue reached $268 million, driven by commercial success and R&D partnerships. The company highlights early launch momentum for TRYNGOLZA.

July 29 Ionis

Ionis announces chief scientific officer Frank Bennett's retirement

Dr. Bennett, a founding scientist, will retire in February 2027 after pioneering RNA-targeted medicines.

July 15 Ionis

Ionis to hold Q2 2026 financial results webcast

The webcast is on July 29 at 8:30 a.m. ET, accessible via Ionis's investor relations page.

July 14 Ionis

Ionis partner Biogen presents Phase 2 CELIA data for diranersen

The data showed robust tau reduction and meaningful clinical outcomes across doses, with the 60 mg dose achieving up to 50% slowing on MMSE.

Media coverage

July 29 Morningstar

Narrow-Moat Ionis' Early Tryngolza Launch Makes Progress and Adds to Positive...

Morningstar is an investment research company offering mutual fund, ETF, and stock analysis, ratings, and data, and portfolio tools. Discover actionable insights today.

July 29 Morningstar

Ionis Earnings: Early Signs of Commercial Momentum for Tryngolza as Key...

Morningstar is an investment research company offering mutual fund, ETF, and stock analysis, ratings, and data, and portfolio tools. Discover actionable insights today.

July 29 Yahoo Finance

Ionis announces Dr. Frank Bennett, chief scientific officer, to retire

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027.

July 23 Yahoo Finance

Ionis Pharmaceuticals (IONS) Misses A Key Trial Endpoint, Is The Valuation Now Too Harsh?

Ionis Pharmaceuticals (IONS) is back in focus after mixed R&D news, with the high profile CARDIO-TTRansform trial for eplontersen missing its primary endpoint, while the...

Never miss news about Ionis

Track Ionis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Ionis competitors & trending companies

Browse news for competitors to Ionis and other trending companies.